InMode (INMD)
(Delayed Data from NSDQ)
$17.16 USD
+0.59 (3.56%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $17.16 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
B Value D Growth C Momentum C VGM
InMode (INMD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$24.00 | $30.00 | $16.00 | 44.84% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for InMode comes to $24.00. The forecasts range from a low of $16.00 to a high of $30.00. The average price target represents an increase of 44.84% from the last closing price of $16.57.
Analyst Price Targets (5 )
Broker Rating
InMode currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, two are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/INMD.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.33 | 2.33 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/23/2024 | Not Identified | Not Identified | Hold | Hold |
7/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/12/2024 | Canaccord Genuity | Caitlin Cronin | Hold | Hold |
7/11/2024 | Needham & Company | Michael Matson | Hold | Hold |
2/14/2024 | UBS | Danielle Antalffy | Hold | Hold |
12/21/2023 | Robert W. Baird & Co. | Jeffrey D Johnson | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 6 |
Average Target Price | $24.00 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 101 of 253 |
Current Quarter EPS Est: | 0.37 |